Accelerating Cures in the Genomic Age: The Sickle Cell ExamplePosted on December 11th, 2018 by Dr. Francis CollinsCredit: Jill George, NIHForty-five years ago, when I was a first-year medical student, a lecturer introduced me to a young man with sickle cell disease (SCD). Sickle cell disease is the first “molecular disease”, with its cause having been identified decades ago. In fact, it inspired some of my earliest research on human hemoglobin disorders, which I conducted as a postdoctoral fellow. Somatic cell gene editing is associated with ethical issues that are much more in line with decades of deep thinking about benefits and risks of therapeutic trials. December 3, 2018Links:Sickle Cell Disease (National Heart, Lung, and Blood Institute/NIH)Cure Sickle Cell Initiative (NHLBI)John Tisdale (NHLBI)Somatic Cell Genome Editing Program (Common Fund/NIH)What are genome editing and CRISPR-Cas9?